TORONTO, ONTARIO–(Marketwired – March 27, 2015) – BlueOcean NutraSciences Inc. (“BlueOcean”) (TSX VENTURE:BOC) is pleased to announce that it has signed a Project Development Agreement (“PDA”) with a commercial algae producer to enhance their current microalgae production using BlueOcean’s proprietary CO2 infusion system. The project will commence on April 15, 2015 and be completed by September 30, 2015 and will include the application of BlueOcean’s CO2 infuser to the commercial algae producer’s current growth system at bench scale. Upon completion of the project and review of the results, the companies may enter into a licensing arrangement to use BlueOcean’s proprietary CO2 infusion system in the commercial algae producer’s algae growth system to attain enhanced algae biomass production.
CO2 Infusion Technology
BlueOcean has the exclusive global license to the CO2 infusion system which uses mass transfer of water-soluble gases such as CO2 into water. The technology infuses CO2 into water at a molecular level by displacing other molecules in the water such as oxygen and nitrogen, and replacing them with carbon dioxide (CO2). The CO2 is infused and completely dissolved into the water in a bubble-less solution to levels up to 1 gram of CO2 per liter of water (maximum CO2 saturation is 1.5 g/L) and can be adjusted to the required CO2 level for the algae strain.
Bubble-less CO2 Benefits
The bubble-less CO2 further stays in solution as they are not in bubbles which rise and gas-off. The bubble-less nature of the CO2 in solution, the high levels of dissolved CO2 in solution, and with the CO2 remaining in solution, makes the CO2 more bio-available to organisms such as microalgae that require CO2 as a nutrient. Since the high amounts of CO2 causes the media pH to drop, a buffer can be added to raise the pH to whatever level is required for the respective strain being grown, yet this adjustment of pH upwards does not result in CO2 off-gas so both the high CO2 levels and optimum pH levels can be achieved. These high levels of CO2 also make it unfriendly for bacteria and other contaminants that require oxygen to survive, thus preventing contamination.
The CO2 infused media has been proven to enhance algae production yields by up to 3 times by Canada’s National Research Council.
The growth trial with the commercial algae producer opens a new commercialization stream for the CO2 infusion technology in addition to its use in BlueOcean’s own algae production system. BlueOcean’s own algae production system is currently being validated at the Arizona Center for Algae Technology and Innovation (AZCATI) where BlueOcean is developing its omega-3 EPA algal oil product, AlgaOmega™ EPA, using the CO2 infusion system to grow enhance algae biomass production for the extraction of the omega-3 algal oil.
About BlueOcean NutraSciences Inc.
BlueOcean NutraSciences Inc. is a Canadian listed public company (TSX VENTURE:BOC) that is focused on developing sustainable, specialty nutraceutical oil products targeted at the rapidly growing Natural Astaxanthin, Krill oil and Omega-3 Algal oil health and wellness markets.
BlueOcean is developing two specialty oil product lines: AstaShrimp™ and AlgaOmega™, and BlueOcean and its JV partner, CMax technologies, have developed a process to convert shrimp, krill, algae and other fish oils into Extended Release Tablets.
BlueOcean owns 50% of the participating and voting rights in 70717 Newfoundland and Labrador Ltd, a joint venture with a major Atlantic Canada shrimp processor that provides the shrimp feedstock for the extraction of Northern AstaShrimp™, and BlueOcean wholly owns the rights to produce and sell its Pacific and Southern AstaShrimp™ oils. BlueOcean wholly owns its AlgaOmega™ product line. BlueOcean owns 50% of the participating and voting rights in 2453969 Ontario Inc., a joint venture with CMax Technologies to develop extended release omega-3/astaxanthin tablets.
The natural oils to be used in AstaShrimp™ contain very high levels of naturally occurring astaxanthin, phospholipids, and omega-3 EPA and DHA. AstaShrimp™ will be targeted at the high value and rapidly growing natural astaxanthin market which is expected to grow to over $700M by 2017. AlgaOmega™ oil is vegetarian, non-GMO omega-3 algal oil containing high levels of EPA with Polar Lipids and is targeted at the rapidly growing omega-3 algal oil ingredient market that is currently valued at $500M and growing at 14% CAGR. The extended release tablets target the rapidly growing $25B omega-3 consumer market and $700M astaxanthin consumer dietary supplements markets.
Forward Looking Statements: BlueOcean
This news release may contain forward-looking statements that are based on BlueOcean’s expectations, estimates and projections regarding its business and the economic environment in which it operates. These statements are not guarantees of future performance and involve risks and uncertainties that are difficult to control or predict. Therefore, actual outcomes and results may differ materially from those expressed in these forward-looking statements and readers should not place undue reliance on such statements. Statements speak only as of the date on which they are made, and the Company undertakes no obligation to update them publicly to reflect new information or the occurrence of future events or circumstances, unless otherwise required to do so by law.
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
View original article at: BlueOcean Signs Project Development Agreement With a Commercial Algae Producer